CytRx's INNO-206 in Combination Therapy Induces Complete Remissions in Aggressively Growing Ovarian Cancer Tumor Model

CytRx Corporation CYTR today announced the achievement of complete remissions in aggressively growing in vivo ovarian cancer tumors treated with a combination of low doses of CytRx's tumor-targeted albumin-binding doxorubicin conjugate INNO-206 and the commonly prescribed cancer treatment doxorubicin. The study evaluated the antitumor efficacy of INNO-206 in an ovarian xenograft cancer model in animals, alone and in comparison to doxorubicin, each at their respective maximum tolerated doses and in combination at half of their respective MTDs. Doxorubicin at its optimal dose showed only a moderate effect in the animal model. In contrast, INNO-206 at its optimal dose induced complete remissions, and the increased effectiveness was statistically significant compared to the doxorubicin-treated group. Administering either drug by itself resulted in significant body weight loss; however, weight loss was significantly reduced when the drugs were given in combination at the lower doses. The results were published on-line ahead of print in the original article, “Combination therapy with albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improved tolerability in an ovarian A2780 xenograft model,” in the peer-reviewed journal Investigational New Drugs (http://www.springerlink.com/content/v4286257326571wm/). Steven Kriegsman, CytRx's President and CEO, said, “This trial exemplifies the importance of our on-going relationship with the inventor of INNO-206, Dr. Felix Kratz, Head of the Division of Macromolecular Prodrugs at the Tumor Biology Center in Freiburg, Germany. We are excited about the progress with INNO-206 and are looking forward to reporting our Phase 1b clinical trial results in soft tissue sarcomas in the coming months.”